Rankings
▼
Calendar
NVAX Q1 2024 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena
NVAX
Novavax, Inc.
$2B
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$94M
+1560.1% YoY
Gross Profit
$45M
48.0% margin
Operating Income
-$139M
-147.8% margin
Net Income
-$148M
-157.2% margin
EPS (Diluted)
$-1.05
QoQ Revenue Growth
-67.8%
Cash Flow
Operating Cash Flow
-$84M
Free Cash Flow
-$91M
Stock-Based Comp.
$12M
Balance Sheet
Total Assets
$1.4B
Total Liabilities
$2.2B
Stockholders' Equity
-$867M
Cash & Equivalents
$481M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$94M
-$6M
+1560.1%
Gross Profit
$45M
-$41M
+211.2%
Operating Income
-$139M
-$313M
+55.6%
Net Income
-$148M
-$294M
+49.8%
Revenue Segments
Product
$82M
88%
Royalties and Other
$12M
12%
Geographic Segments
Europe
$90M
110%
Rest of the World
-$2M
-2%
North America
-$6M
-8%
← FY 2024
All Quarters
Q2 2024 →